350595-57-2

Basic information

• Product Name: 3S-3-METHYLMORPHOLINE
• Synonyms: 3S-3-METHYLMORPHOLINE;(S)-3-Methylmorpholine;(S)-3-MethylMorpholine HCl;Morpholine, 3-Methyl-, (3S)-;3S-3-Methylmorpholine(WX604204)
• CAS NO: 350595-57-2
• Molecular Formula: C₅H₁₁NO
• Molecular Weight: 101.15
• Product Categories: Amines;Heterocycles;Inhibitors
• Mol File: 350595-57-2.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 137.1 °C at 760 mmHg
• Flash Point: 41.3 °C
• Appearance: /
• Density: 0.891 g/cm³
• Vapor Pressure: 7.14mmHg at 25°C
• Refractive Index: 1.409
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.03±0.40(Predicted)
• CAS DataBase Reference: 3S-3-METHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3S-3-METHYLMORPHOLINE(350595-57-2)
• EPA Substance Registry System: 3S-3-METHYLMORPHOLINE(350595-57-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• RIDADR: 2735
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 350595-57-2(Hazardous Substances Data)

Usage

Description

(3S)-3-Methylmorpholine is an organic compound that belongs to the morpholine class. It is a chiral molecule with a specific stereochemistry, characterized by the presence of a methyl group at the 3-position and a stereocenter at the same position. 3S-3-METHYLMORPHOLINE serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting specific kinases.

Uses

Used in Pharmaceutical Industry:
(3S)-3-Methylmorpholine is used as a key intermediate in the synthesis of morpholinopyrimidine derivatives. These derivatives act as mTOR kinase inhibitors, which are crucial for the treatment of diseases mediated by mTOR kinase and/or one or more PI3K enzymes. The inhibition of these kinases can help in controlling the progression of various diseases, including cancer and other conditions related to unregulated cell growth and proliferation.

InChI:InChI=1/C5H11NO/c1-5-4-7-3-2-6-5/h5-6H,2-4H2,1H3/t5-/m0/s1

Upstream product

• 120800-91-1 (3S)-3-methyl-4-(phenylmethyl)morpholine 
• 119844-66-5 (S)-5-methylmorpholin-3-one 
• 119128-21-1 (5S)-5-methyl-4-(phenylmethyl)-3-morpholinone 
• 94193-79-0 2-chloro-N-((S)-2-hydroxy-1-methylethyl)acetamide 
• 122116-12-5 2-(prop-2-yn-1-yloxy)ethan-1-amine 
• 634926-63-9 N-(tert-butyloxycarbonyl)-2-(propargyloxy)aminoethane 
• 42185-06-8 3-methylmorpholine 

Downstream Products

• 1013402-38-4 N-[2-[[6-chloro-2-[(3S)-3-methylmorpholin-4-yl]pyrimidin-4-yl]amino]phenyl]-2,2-difluoro-acetamide 
• 944953-94-0 2-[(3S,4R,5R)-4-(4-methoxyphenyl)-5-[4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethoxy]-1-(toluene-4-sulfonyl)piperidin-3-yloxy]-1-((S)-3-methylmorpholin-4-yl)ethanone 
• 1051899-25-2 (S)-3-(3-methylmorpholino)-5-morpholinoaniline 
• 1051901-15-5 4,4'-(5,5'-dinitrobiphenyl-3,3'-diyl)dimorpholine 
• 1009628-46-9 2-chloro-4-[(4-fluorophenyl)sulfonylmethyl]-6-[(3S)-3-methylmorpholin-4-yl]pyrimidine 
• 1009627-53-5 4-(benzenesulfonylmethyl)-2-chloro-6-[(3S)-3-methylmorpholin-4-yl]pyrimidine 
• 1116229-31-2 (3S)-3-methyl-4-[3-(methyloxy)-4-nitrophenyl]morpholine 
• 1049809-90-6 4-(3-chloro-propyl)-3-methyl-morpholine 
• 1201798-98-2 5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxybenzyl pivalate 
• 1009298-82-1 methyl 5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxybenzoate 
• 1199878-42-6 C₂₂H₂₇ClN₆O 
• 1049098-72-7 1-[(3S)-3-Methylmorpholin-4-yl]-3-[5-(methylsulfonyl)-3-{3-[(2-morpholin-4-yl-2-oxoethyl)sulfanyl]-4-(trifluoromethyl)phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol 
• 1241910-76-8 (S)-4-(3-methylmorpholino)benzonitrile 
• 1252575-72-6 (S)-4-(4-bromo-3-fluorobenzyl)-3-methylmorpholine 

Relevant articles and documents

Acylative kinetic resolution of racemic methyl-substituted cyclic alkylamines with 2,5-dioxopyrrolidin-1-yl (: R)-2-phenoxypropanoate

The diastereoselective acylation of a number of racemic methyl-substituted cyclic alkylamines with active esters of 2-phenoxypropanoic acid was studied in detail. The ester of (R)-2-phenoxypropanoic acid and N-hydroxysuccinimide was found to be the most selective agent. The highest stereoselectivity was observed in the kinetic resolution of racemic 2-methylpiperidine in toluene at -40 °C (selectivity factor s = 73) with the predominant formation of (R,R)-amide (93.7% de). To explain the observed stereoselectivity, DFT modelling of the transition states in the reactions of the title acylating agent with 2-methylpiperidine and 2-methylpyrrolidine was performed. The calculated values were in good agreement with experimental data. It has been demonstrated that the acylation proceeds via a concerted mechanism, in which the addition of an amine occurs simultaneously with the elimination of the hydroxysuccinimide fragment. The high stereoselectivity of the (R,R)-amide formation is largely ensured by the lower steric hindrances in the transition states as compared to the formation of (R,S)-amide.

Preparation method of (S)-(4-bromine-2-methylbenzene) (3-N-methylmorpholine) ketone

The invention discloses a preparation method of (S)-(4-bromine-2-methylbenzene) (3-N-methylmorpholine) ketone, and belongs to the technical field of organic synthesis. The invention is characterized in that the preparation method of the (S)-(4-bromine-2-m

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway